Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased ...

Aptar CSP Technologies has developed a dual-active material science technology designed to simultaneously control moisture ...

Adrenal adenomas were associated with attenuated weight loss among patients with obesity or overweight using GLP-1 or GIP/GLP-1 RAs.

According to a new report from Big Chalk Analytics, GLP-1 users have cut $6.5 billion from U.S. grocery spend.

A recent Mercer survey reveals that over half of large employers plan to shift more health care costs to employees amid rising expenses expected in 2026.

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best oversold NASDAQ stocks to buy now. On June 30, H.C. Wainwright ...

Why confectionery giants are investing in snacks - from health pressures to shifting consumer habits, the future of food is ...